Second FDA Import Ban Increases Wockhardt’s Regulatory Hurdles

Generic Line
The FDA Nov. 27 hit Wockhardt with a second “import alert,” banning drug products from its Chikalthana plant in western India — the latest in a spate of regulatory actions taken against the struggling drugmaker.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00